| 摘要 |
One or more of the phytocannabinoids tetrahydrocannabivarin (THCV), cannabigerol (CBG), cannabichromene (CBC), or cannabidivarin (CBDV) for use in the treatment of intestinal inflammatory diseases. Preferably the intestinal inflammatory disease is either ulcerative colitis or Crohn's disease. The one or more phytocannabinoids may be synthetic or isolated. The one or more phytocannabinoids may be present as an extract from a cannabis plant, preferably a botanic drug substance. The botanical drug substance preferably comprises a phytocannabinoid-containing component comprising greater than 50% (w/w) of the botanical drug substance (BDS) and a non-phytocannabinoid containing component comprising less than 50% (w/w) of the BDS. The non-phytocannabinoid containing component may comprise terpenes, sterols, triglycerides, alkanes, squalenes, tocopherols, and carotenoids. |
